Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Regulatory & Legal

TITLE:

EMA: On the 18 September 2017, the European Commission granted a Marketing Authorisation for Bavencio (avelumab), indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).The Marketing Authorization Holder for this medicinal product is Merck Serono Europe

BRIEF:

EMA: EC granted the Marketing Authorisation for Bavencio (avelumab) 20 mg/mL concentrate for solution for infusion from Merck Serono Europe. Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). (ATC code: L01XC).

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company